FDA grants pozelimab-bbfg approval as the first treatment for adults and children with CHAPLE disease.

Published Date: 24 Aug 2023

A phase 2/3 trial that examined the safety and effectiveness of pozelimab-bbfg claims that all 10 patients normalized their serum albumin and IgG concentrations by week 12 according to Regeneron. The 72 weeks saw no change in these concentrations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer

2.

Pediatric high-grade gliomas: Research reveals effective targeting with avapritinib

3.

In prostate cancer survivorship, sleep disturbances are underappreciated.

4.

Study shows supervised exercise improves strength, physical performance in patients with advanced breast cancer

5.

a cutting-edge cancer diagnostic tool.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot